First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer
We're thrilled to share that the first patient has been treated in a Phase I study of NILK-2301, a groundbreaking κλ body-based CEACAM5-targeting T cell engager (CEACAM5xCD3 bispecific antibody) for the immunotherapy of CEACAM5-expressing cancers.
Light Chain Bioscience | Novimmune SA, in partnership with LamKap Bio Group, is leading the charge in the clinical development of this innovative therapy in collaboration with two esteemed clinical hospitals highly experienced in early clinical development and immunotherapy of cancer, Val d’Hebron Institute of Oncology (VHIO) and START Madrid – FJD, led by Prof Josep Tabernero and Victor Moreno respectively.
It's an honor to contribute to the lives of solid cancer patients. A heartfelt thank you to the patients and their families for entrusting us with their care.
If you're interested in learning more about NILK-2301, check out the manuscript detailing its development and characterization here: publication in Journal of Hematology & Oncology.
April 29th, 2024
